Infectious Disease Treatments Market Size was valued at USD 58.02 Billion in 2023. The Global Infectious Disease Treatments industry is projected to grow from USD 62.94 Billion in 2024 to USD 116.83 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.11% during the forecast period (2024 - 2032).
Infectious diseases can be caused by a variety of organisms that are inclusive of bacteria, viruses, fungi, and parasites. Some infectious diseases are contagious and can be passed from person to person. Few of these infectious diseases are transmitted by the bites of insects or animals while few are also acquired by ingestion of contaminated water or food. Some of the common examples of infectious diseases are acquired immunodeficiency syndrome (AIDS), hepatitis B, tuberculosis (TB), and others. Increasing prevalence of the infectious diseases like TB, AIDS, and others across the globe is one of the major drivers for the growth of the infectious disease treatments market during the forecast period. In 2016, according to the Centers for Disease Control and Prevention, TB affected one-third of the world’s population. Moreover, it was estimated that 10.4 million people around the world were detected with TB disease and the disease led to 1.7 million, people globally. Additionally, according to the World Health Organisation, in 2016, 36.7 million people lived with HIV/AIDS and the disease caused 1.0 million deaths, globally. Besides this, increasing healthcare expenditures, growing awareness of the patients will further boost the infectious disease treatments market growth. However, low adoption of the treatment and low per capita healthcare expenditure in the developing economies may restrain the infectious disease treatments market growth during the forecast period.
Disorders brought on by germs like bacteria, viruses, fungi, or parasites are known as infectious diseases. They are frequently favorable or even secure. However, certain bacteria can cause disease in certain situations. There is a chance that some contagious illnesses will be transmitted from one man to another. Insects or animals transmit others. Contagious illnesses that can spread from person to person include several infectious diseases. A small number of these transmissible illnesses are spread through the stings of insects or other animals, and a smaller number are also contracted using tainted food or water. Acquired immunodeficiency syndrome, tuberculosis, hepatitis B, and others are typical infectious diseases.
One of the key factors propelling the growth of the market for infectious illness treatments throughout the forecast period is the rising prevalence of transmissible illnesses like TB, AIDS, and others worldwide. The rise in the incidence of infectious diseases, the rising prevalence of funding for research and development, and the expanding prevalence of infectious illnesses are the main drivers of the expansion of the market for pharmaceuticals treating infectious diseases. As a result, it is anticipated that the prevalence of infectious diseases will increase, leading to a high growth in the market for infectious medications. It is projected that the advancement of genomics and proteomics will accelerate market expansion. The infectious disease testing products marketplace is expected to be boosted by additional factors such as growing government-funded programs, shifting from centralized labs to dispersed point-of-care testing, and a growing desire for tailored treatments.
News:
Through the potential of pathogen genomes, the World Health Organization and its affiliates are establishing an international network to assist in defending people against the dangers of infectious diseases. The International Pathogen Surveillance Network (IPSN) will offer a platform to connect nations and areas, enhancing systems for gathering and analyzing sample data, using this information to influence public health decisions, and disseminating that data more widely. The IPSN brings together specialists from governments, charitable foundations, international organizations, civil society, academia, and the corporate sector who are at the bleeding edge of genomics and data analytics. Its Secretariat is housed inside the WHO Hub for Pandemic and Epidemic Intelligence. All of them have the same objective: to improve regular disease surveillance and identify and address health hazards before they develop into epidemics and pandemics.
The infectious disease treatments market is segmented on the basis of type, treatment, and end users.
On the basis of the type, the infectious disease treatments market is segmented into viral diseases, bacterial diseases, and others. The viral diseases segment is sub-segmented into acquired immunodeficiency syndrome (AIDS), hepatitis B, hepatitis C, and others. The bacterial diseases segment is sub-segmented into tuberculosis (TB), bacterial meningitis, and others.
On the basis of the treatment, the infectious disease treatments market is segmented into antibacterial drugs, antifungal drugs, antiviral drugs, anti-parasitic drugs, and others. The antibacterial drugs segment is sub-segmented into beta-lactams, quinolones, sulfonamides, tetracyclines, and others. The antifungal drugs segment is sub-segmented into azoles, pyrimidines, echinodians, polyenes, and others.
On the basis of application, the infectious disease treatments market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
On the basis of the end users, the infectious disease treatments market is segmented into hospitals & clinics, research organization, retail pharmacies, and others.
News:
Researchers at the Albert Einstein College of Medicine discovered that the virus that causes chikungunya fever can propagate directly from cell to cell. This finding may help explain how the virus, which is now posing a serious threat to human health, can avoid being neutralized by bloodstream antibodies. The research recently appeared in the journal Nature Microbiology, points to new directions for developing vaccines or other treatments for chikungunya fever, a crippling and increasingly widespread mosquito-borne illness. Chikungunya infections frequently result in chronic and crippling arthritis in addition to fever. Infected mosquitoes pick up the virus by feeding on sick persons and can bite humans and transmit it to them.
The Americas dominate the infectious disease treatments market. A well-developed healthcare sector and huge patient population for infectious diseases followed by increasing healthcare expenditure and changing lifestyle drive the infectious disease treatments market growth in the Americas. Moreover, the presence of global players like Merck & Co., Inc., Pfizer Inc., and others within the region fuels the infectious disease treatments market growth during the forecast period.
Europe is the second largest infectious disease treatments market. High healthcare expenditures, government support for research & development, and huge patient population drives the European market. Moreover, the presence of the developed economies within the region like Germany, the U.K, and France fuels the infectious disease treatments market growth during the forecast period.
Asia Pacific is the fastest growing region in the global infectious disease treatments market due to the presence of a huge patient population and continuously developing economies like India and China which have a growing healthcare industry. Additionally, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax in India boosts the regional market growth.
On the other hand, the Middle East & Africa holds the least share in the global infectious disease treatments market due to the presence of poor economies in the African region. Moreover, the low per capita income and stringent government policies restrain the infectious disease treatments market growth within the African region. A majority of the market in the Middle East & Africa is held by the Middle East due to huge healthcare expenditures and presence of developed economies like Kuwait, Saudi Arabia, Dubai, and Qatar.
Key players for infectious disease treatments market
Intended Audience
Pharmaceutical Companies
Biotechnological Institutes
Research and Development (R&D) Companies
Medical Research Laboratories
Market Research and Consulting Service Providers
| Report Attribute/Metric | Details |
| Market Size | 2032: USD 116.83 Billion |
| CAGR | 7.11% (2024-2032) |
| Base Year | 2021 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, and End users |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), AstraZeneca (U.K), Novartis AG (Switzerland), Sanofi (France), Mylan N.V. (U.S.), and others |
| Key Market Opportunities | Increasing healthcare expendituresGrowing awareness of the patients |
| Key Market Drivers | Increasing prevalence of the infectious diseases |
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
